DC
ADMA icon

Diametric Capital’s ADMA Biologics ADMA Stock Holding History

Diametric Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Buy
+52,005
New +$821K 0.12% 233
2020
Q4 		– Sell
-48,355
Closed -$116K – 162
2020
Q3 		$116K Buy
+48,355
New +$133K 0.09% 111

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Diametric Capital's ADMA Position: Q1 2026 in Review

Diametric Capital opened a new position in ADMA Biologics (ADMA) in Q1 2026: 52,005 shares worth $469K. The stake represents 0.12% of the portfolio and ranks #233 among its holdings. This is a return to the name: Diametric Capital previously reported a position in ADMA as recently as Q3 2020.

Diametric Capital first reported a position in ADMA in Q3 2020 and has held it in 2 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Diametric Capital held 52,005 shares of ADMA Biologics worth $469K as of Q1 2026.
  • ADMA Biologics was a new Diametric Capital position in Q1 2026.
  • ADMA Biologics made up 0.12% of Diametric Capital's portfolio in Q1 2026, its #233 holding.
  • Diametric Capital first reported a position in ADMA Biologics in Q3 2020 and has held it in 2 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.